| Literature DB >> 32527326 |
Wasef Na'amnih1, Amir Ben Tov2,3, Amna Bdair-Amsha1, Shlomi Cohen3, Judith Tsamir2, Gabriel Chodick1,2, Khitam Muhsen4.
Abstract
BACKGROUND: Primary care physicians (PCPs) play a pivotal role in the management of illnesses of the digestive tract. The study aim was to assess the adherence of PCPs to the guidelines on the management of Helicobacter pylori (H. pylori) infection and gastroesophageal reflux disease (GERD) in adults.Entities:
Keywords: Gastroesophageal reflux disease; Guidelines; Helicobacter pylori; Primary care physicians; Survey
Mesh:
Year: 2020 PMID: 32527326 PMCID: PMC7291643 DOI: 10.1186/s13584-020-00389-y
Source DB: PubMed Journal: Isr J Health Policy Res ISSN: 2045-4015
Characteristics of the respondents and non-respondents to the questionnaire
| Primary care physician | |||
|---|---|---|---|
| Respondents | Non-respondents | 0.3 | |
| Age, mean (SD), years | 53.6 (12.0) | 54.6 (10.7) | 0.09 |
| Sex, males | 104 (61%) | 229 (53%) | 0.02 |
| Started to work at MHS from 2010 onward | 67 (39%) | 127 (30%) | 0.7 |
| Employment type, self-employed | 147 (86%) | 359 (84%) | 0.3 |
* Missing data: Nine respondents; one non-respondent
MHS: Maccabi Healthcare Services; SD: standard deviation
Self-reported practices of primary-care physicians in the management of H. pylori infection in adults
| Number/Total (percent) | Weighted Percent* | |
|---|---|---|
| Suspected duodenal or gastric ulcer | 153/180 (85%) | 84% |
| First degree relatives with gastric cancer | 83/180 (46%) | 47% |
| Unexplained iron deficiency anemia | 109/180 (61%) | 59% |
| Before starting long-term use of aspirin or NSAIDs in patients with a history of peptic disease | 82/180 (46%) | 44% |
| Triple therapy with PPIs/clarithromycin/amoxicillin or metronidazole | 141/171 (83%) | 82% |
| Quadruple therapy based on Bismuth | 15/171 (9%) | 9% |
| Quadruple therapy non-Bismuth | 7/171 (4%) | 4% |
| Refer to gastroenterologist | 2/171 (1%) | 2% |
| Other | 6/171 (3%) | 3% |
| 7 days | 15/171 (9%) | 8% |
| 10 days | 83/171 (48%) | 51% |
| 14 days | 65/171 (38%) | 36% |
| Other | 8/171 (5%) | 5% |
| UBT at least 1 month after therapy | 95/171 (56%) | 57% |
| Refer to specialist in gastroenterology | 4/171 (2%) | 1% |
| Stool antigen detection EIA at least 1 month after therapy | 2/171 (1%) | 1% |
| Serology at least 1 month after therapy | 5/171 (3%) | 2% |
| Do not refer to a test if symptoms resolve | 58/171 (34%) | 34% |
| Other | 7/171 (4%) | 5% |
| Refer to a specialist in gastroenterology | 74/171 (43%) | 45% |
| Do not refer to a test if symptoms resolve | 43/171 (25%) | 23% |
| Recommend the same treatment for a longer duration | 5/171 (3%) | 2% |
| Recommend a different treatment | 49/171 (29%) | 30% |
* Percentage obtained by inverse probability weighting
** Physicians who answered “always” or “usually”
EIA: Enzyme immunoassay; NSAID: non-steroidal anti-inflammatory drugs; PPIs: proton pump inhibitors; UBT: Urea breath test
Factors related to primary-care physicians’ referrals of adults for H. pylori infection testing
| Clinical characteristics of the patients referred for testing | Type of testing | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suspected duodenal or gastric ulcer | First-degree relatives of gastric cancer patients | Unexplained IDA | History of peptic disease, before long-term use of NSAIDs | UBT/stool antigen EIA in test-and-treat strategy | Endoscopy/specialist-alarm symptoms | |||||||||||||
| Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |||||||
| Number | 146 | 25 | 78 | 93 | 102 | 69 | 76 | 95 | 136 | 27 | 160 | 8 | ||||||
| Age, mean (SD) | 52.6 (12.3) | 59.2 (8.2) | 0.02 | 55.0 (10.4) | 52.4 (13.1) | 0.3 | 52.7 (11.9) | 54.8 (12.1) | 0.2 | 53.3 (12.6) | 53.8 (11.6) | 0.8 | 52.5 (12.4) | 58.2 (9.0) | 0.04 | 53.9 (12.0) | 52.0 (10.9) | 0.6 |
| Years since board certification, mean (SD) | 19.2 (12.5) | 24.1 (10.3) | 0.1 | 19.7 (11.6) | 20.0 (13.1) | 0.7 | 18.0 (12.7) | 22.8 (11.1) | 0.02 | 19.9 (12.4) | 19.9 (12.3) | 0.9 | 18.5 (12.2) | 5.4 (12.3) | 0.006 | 19.6 (12.3) | 24.3 (12.8) | 0.3 |
| Started to work at MHS 2010 onward, n (%) | 62 (43) | 5 (20) | 0.03 | 28 (36) | 39 (42) | 0.4 | 47 (46) | 20 (29) | 0.03 | 30 (40) | 37 (39) | 0.9 | 56 (41) | 6 (22) | 0.06 | 58 (38) | 2 (33) | 0.8 |
| 124 (84) | 20 (77) | 0.3 | 72 (91) | 72 (77) | 0.01 | 88 (86) | 56 (79) | 0.2 | 68 (84) | 76 (83) | 0.8 | 116 (84) | 27 (80) | 0.5 | 136 (85) | 4 (50) | 0.03 | |
EIA: enzyme immunoassay; IDA: iron deficiency anemia; MHS: Maccabi Healthcare Services; NSAIDs: non-steroidal anti-inflammatory drugs UBT: urea breath test; SD: standard deviation
Self-reported practices of primary-care physicians in the management of gastroesophageal reflux disease in adults (N = 168)
| Number | Weighted | |
|---|---|---|
| 10 (6%) | 5% | |
| 138 (82%) | 82% | |
| 165 (98%) | 99% | |
| 134 (80%) | 83% | |
| 157 (94%) | 94% | |
| 139 (83%) | 84% | |
| 159 (95%) | 94% |
* Physicians who answered “always” or “usually” out of 168 responders to this part
** Inverse probability weighting
PPIs: proton pump inhibitors; GERD: gastroesophageal reflux disease